



NASDAQ: MDBH

We Launch Big Ideas

Second Quarter 2025 Update
August 27, 2025

This presentation contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the SEC. The forward-looking statements included in this message represent MDB's views as of the date of this message. MDB anticipates that subsequent events and developments will cause its views to change. MDB undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing MDB's views as of any date subsequent to the date of this presentation.

Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. Past performance is not indicative of future results.

As part of our obligation to help you better understand what we do, compared to other brokerage firms in the industry, we are providing you with our Client Relationship Summary, or Form CRS. Form CRS is the uniform disclosure that provides succinct information about a firm's services and responsibilities, fees and costs, and standards of conduct. Please follow this link to review MDB Capital's Form CRS: <https://www.mdb.com/disclosures/customer-relationship-summary/>

Financial Perspective

- MDB revenue is largely financings
- Goal is to offset operating expenses with financings
- Equity in financed companies is real upside for shareholders
- Always a balance of “Big Ideas” we incubate and current revenue from launching more developed companies
 - More equity vs. more fee income
- Being cautious to balance operating expenses and revenue until our equity positions pay-off
- Net cash use in operational activities approximately \$3.4 million for first half 2025
- Expect to be closing financings in second half 2025 to reduce or eliminate cash usage

Public Venture Momentum is Building...

We're confident in what we've built:

The most unique, and capable platform to curate and deliver market-leading companies that have 10-100 bagger potential

We've proven it works over the past 28 years.

We're getting great response:

From new investors and advisers who get exposed to our approach as we scale it.

We recognize two key bottlenecks to address:

1. Investor hesitation toward deep tech life science investments right now.
2. The need to scale our investor community to support more high-quality opportunities we curate.

Realizing the promise of what we've built

1. Expand our product mix

- Bring investors what they want to invest in now:

Opportunities in profitable, growing early-stage companies with asymmetrical return potential and public market liquidity

- MDB is uniquely positioned to add value to opportunities beyond life sciences

2. Expand our distribution

- Reach and attract new investors and partners excited about public venture
- MDB provides an attractive alternative for allocating capital vs. traditional venture or angel investing

Product Mix: What We Have Learned

- Early-stage life sciences companies lacking revenue momentum or profitability are struggling.
 - These companies are taking longer to develop
 - Investors want to balance quicker returns with venture bets
- Profitable growing companies with revenue momentum are highly valued in the current market.
- We see a big opportunity to bring these companies into the public marketplace

Expanding the MDB product mix to include profitable companies with revenue momentum

- More responsive product mix to opportunities investors want *today*
- Include companies that are profitable with revenue momentum and the asymmetrical potential returns of public venture
- Continue to focus only on companies that can become new leaders or create new categories
- Enables MDB to get more deals done by expanding investor interest beyond life sciences

Our Next IPO: Buda Juice

Launching our first IPO for a profitable company in MDB's history



**BUDA
JUICE**

- Profitable and rapidly growing private fresh juice company ready for nationwide expansion
- Redefining the fresh juice category is a “Big Idea”
- **UltraFresh™** cold-crafted juices are creating a new category and gold standard in fresh juice - \$8.7 billion market
- Unique 35F° continuous cold chain process is unmatched
- Enables **all** grocery stores to sell **UltraFresh™** cold-crafted juices

Filed S-1 today

Roadshow begins on September 4, 2025

We believe the public market is the place to be

- A dramatic market shift is occurring...away from private equity and traditional venture capital toward public venture
- More companies with developed businesses are coming to MDB because they want to go public
- Entrepreneurs that run these companies are recognizing the drawbacks of private equity and traditional venture
- Public venture provides them a preferable solution to raise capital or gain liquidity
- Not many underwriters have the process or platform to take early-stage companies public like MDB

Metabolic health epidemic: The biggest Healthcare opportunity of our time

- Obesity and diabetes therapies are expected to **dwarf all other therapeutic categories, representing a market worth hundreds of billions of revenue**
- Over **890 million adults worldwide** are affected by obesity and the number of adults with Type 2 diabetes (T2D) is projected to reach **784 million by 2045**.
- Obesity and T2D are major drivers of cardiovascular disease, liver disease (NASH), and disability.
- Many current therapies fail to address root causes or offer scalable solutions.

We believe any drugs or interventions that complement or replace GLP-1s for certain patients will drive huge market values – 10-100 baggers

Three potential market leading companies that hold the promise of a “metabolic switch” and 100 bagger potential and near term value increase potential

Paulexβio

Small molecule drugs regenerating pancreatic beta cells—synergistic with GLP-1 agonists **with near term big value readout**

First to Enable Human Beta Cell Regeneration

NCTx
exoZymes

Biomanufactured NCT mobilizing pathogenic organ fat in liver/pancreas—potential for reversing NASH, T2D, and improving gut health **with near term commercialization potential.**

First commercial biomanufacture of NCT


GT Metabolic™

Minimally invasive magnetic “metabolic switch” with impressive patient data emerging and **ramping revenue quickly**

First-in-Human, Incisionless Duodenal Bypass via Swallowable Magnets

Expanding our investor community with Angel groups and RIAs

What We've Learned

- Public venture is increasingly appealing to investors and advisers who previously focused on traditional venture or angel opportunities
- Lengthy investment hold times before liquidity are a major downside
- The combination of MDB track record and public venture strategy is preferable vs. traditional venture to these groups

MDB and Keiretsu Forum MST partnership drives new IPO Angels platform

- New platform open to **Keiretsu Forum** Mid-Atlantic, Southeast and Texas (K4-MST) members
 - Part of world's largest and most successful accredited investor – private equity community
 - Facilitated over \$39 million in direct member investments over past three years
- Provides access to MDB curated public venture opportunities
- Combines elite deal flow with accelerated path to IPOs and predictable liquidity for investors

Open to accredited angel investors, members of angel groups, and family offices by invitation

Expanding our investor community will enable more investment opportunities per year

RIAs

- In discussion with multi-billion dollar RIAs where MDB can become key public venture manager for alternative allocations and provide PatentVest diligence services.

New Age Distribution Platforms

- Regulation is changing the way investments are sold
- Reg A+ allowing advertising of investments
- New platforms are allowing small investors to access IPOs and see high-quality, “curated” investment opportunities



PATENTVEST

The Next Generation IP Law Firm

- AI is transforming the practice of law, especially IP law. A firm that embraces best practices will flourish.
- As a **public** ABS law firm
 - Acquire existing law firms to become development partners
 - Partner with existing clients financially in litigation and IP development like no other law firm can
- New opportunity to significantly scale operations has emerged
 - Combining AI with PatentVest's proprietary processes and database provides unmatched resources for the best US patent attorneys

MDB planning to spin-out PatentVest as its own public company in 2026

MDB

INVESTOR EVENT

Experience MDB in-person

Join us in Dallas on September 4

- Meet the MDB team
- Discover our Public Venture strategy in greater detail
- Learn about new opportunities in Metabolic Health
- Get to know our next IPO opportunity – Buda Juice
- Learn more about our new partnership with Keiretsu MST and IPO Angels
- Meet and talk with leaders from our portfolio companies



**INVESTOR
SUMMIT 2025**

September 4, 2025



Old Parkland, Dallas

[Register Now](#)



**Lunch & Program
Seating Limited**

Building leadership and momentum

Investors will continue to rely on MDB's platform and experience to curate the best public venture opportunities.

Grow our leadership in public venture by:

- Expanding our product mix to meet current investor demand.
- Expanding our distribution to fund more opportunities with angels and RIAs.
- Continuing to curate the best early-stage companies with the potential to become market leaders in new categories.
- Further leveraging our unique asset in PatentVest to become an independent public company contributing even greater value to MDB.

Questions